Gallant and MWI have partnered to give veterinary practices safe and reliable access to off-the-shelf stem cell therapies.

Zahra Mahmoudjafari explains how cell and gene therapy programs succeed with strong infrastructure, pharmacy leadership, ...

With $55 billion earmarked to bolster its U.S. operations, Johnson & Johnson is the latest drugmaker to zero in on expansion ...

Phase 1 ATLAS trial to evaluate TK-6302 in patients with advanced PRAME-positive solid tumors authorized for initiation ...

Six pregnant women participated in a small trial in which placenta-derived stem cells were applied to fetal spinal cords and the treatment was found to be safe.

A first-in-human trial shows the feasibility and safety of delivering placenta-derived stem cells during prenatal ...

The first engineered cell therapy has come to the fight against solid tumors. Fox Chase Cancer Center has begun using Tecelra, an FDA-approved treatment for synovial sarcoma.

A new, highly sensitive cell therapy was able to wipe out three different kinds of solid tumors in mice, an important advance in an area where CAR-T cells have long struggled. But significant ...

In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite prostaglandin E2 can block T cells—the killer cells of the immune system—in the ...

Once fully operational, the Pennsylvania site will employ more than 500 people and make cell therapies for thousands of patients a year.

Johnson & Johnson, the healthcare and lifestyle giant announced a more than $1 billion dollar investment in next generation ...

Cell therapy manufacturing is uniquely vulnerable to contamination, variability, and operational burden because the product - ...